Outlook Therapeutics has appointed Kevin Michael Lundquist as chief financial officer, and he has reported an initial insider position in the company. The update matters to investors because it identifies a new senior financial executive and records Lundquist’s status as an insider at the Nasdaq-listed company.

Key Highlights

  • Kevin Michael Lundquist now holds the chief financial officer role at Outlook Therapeutics.
  • Lundquist reported an initial stake in the company as a new insider.
  • Outlook Therapeutics trades on Nasdaq under the symbol OTLK.

Outlook Therapeutics, Inc. (NASDAQ: OTLK) has named Kevin Michael Lundquist as its chief financial officer. Lundquist is also associated with an initial stake and a new insider position at the company.

Investor Insights

The same update records his new status as an insider at Outlook Therapeutics. Outlook Therapeutics is listed on Nasdaq under OTLK.